Skip to main content

Table 6 Multivariate analysis for OS and PFS without RPA.

From: Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life

Overall Survival (OS)

P value

Tumour control (SD, CR, PR)

<0.0001

Brain progression (PD)

 

KPS ≤60

0.002

KPS >60

 

Age ≤65 years

0.01

Age >65 years

 

Progression Free Survival (PFS)

P value

Tumor control (SD, CR, PR)

<0.0001

Brain progression (PD)

 

KPS ≤60

0.003

KPS >60

 

No extracranial disease

0.325

Extracranial disease

 

Age >65 years

0.01

Age ≤65 years